vs
Side-by-side financial comparison of JFrog Ltd (FROG) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
JFrog Ltd is the larger business by last-quarter revenue ($145.3M vs $103.7M, roughly 1.4× Twist Bioscience Corp). JFrog Ltd runs the higher net margin — -10.5% vs -29.4%, a 19.0% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs 16.9%). JFrog Ltd produced more free cash flow last quarter ($49.9M vs $-34.8M).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
FROG vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $103.7M |
| Net Profit | $-15.2M | $-30.5M |
| Gross Margin | 77.9% | 52.0% |
| Operating Margin | -14.7% | -31.7% |
| Net Margin | -10.5% | -29.4% |
| Revenue YoY | 25.2% | 16.9% |
| Net Profit YoY | 34.4% | 3.4% |
| EPS (diluted) | $-0.13 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $145.3M | $103.7M | ||
| Q3 25 | $136.9M | — | ||
| Q2 25 | $127.2M | — | ||
| Q1 25 | $122.4M | — | ||
| Q4 24 | $116.1M | — | ||
| Q3 24 | $109.1M | — | ||
| Q2 24 | $103.0M | — | ||
| Q1 24 | $100.3M | — |
| Q4 25 | $-15.2M | $-30.5M | ||
| Q3 25 | $-16.4M | — | ||
| Q2 25 | $-21.7M | — | ||
| Q1 25 | $-18.5M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q3 24 | $-22.9M | — | ||
| Q2 24 | $-14.3M | — | ||
| Q1 24 | $-8.8M | — |
| Q4 25 | 77.9% | 52.0% | ||
| Q3 25 | 77.4% | — | ||
| Q2 25 | 76.3% | — | ||
| Q1 25 | 75.3% | — | ||
| Q4 24 | 75.4% | — | ||
| Q3 24 | 75.0% | — | ||
| Q2 24 | 78.8% | — | ||
| Q1 24 | 79.5% | — |
| Q4 25 | -14.7% | -31.7% | ||
| Q3 25 | -15.8% | — | ||
| Q2 25 | -20.4% | — | ||
| Q1 25 | -18.8% | — | ||
| Q4 24 | -21.9% | — | ||
| Q3 24 | -27.4% | — | ||
| Q2 24 | -18.6% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | -10.5% | -29.4% | ||
| Q3 25 | -12.0% | — | ||
| Q2 25 | -17.0% | — | ||
| Q1 25 | -15.1% | — | ||
| Q4 24 | -20.0% | — | ||
| Q3 24 | -21.0% | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | -8.8% | — |
| Q4 25 | $-0.13 | $-0.50 | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.19 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-0.21 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $887.4M | $456.1M |
| Total Assets | $1.3B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $704.4M | $197.9M | ||
| Q3 25 | $651.1M | — | ||
| Q2 25 | $611.7M | — | ||
| Q1 25 | $563.5M | — | ||
| Q4 24 | $522.0M | — | ||
| Q3 24 | $467.8M | — | ||
| Q2 24 | $591.3M | — | ||
| Q1 24 | $579.6M | — |
| Q4 25 | $887.4M | $456.1M | ||
| Q3 25 | $859.4M | — | ||
| Q2 25 | $826.5M | — | ||
| Q1 25 | $800.0M | — | ||
| Q4 24 | $773.5M | — | ||
| Q3 24 | $756.2M | — | ||
| Q2 24 | $721.4M | — | ||
| Q1 24 | $707.8M | — |
| Q4 25 | $1.3B | $638.1M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $997.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | $-24.8M |
| Free Cash FlowOCF − Capex | $49.9M | $-34.8M |
| FCF MarginFCF / Revenue | 34.3% | -33.5% |
| Capex IntensityCapex / Revenue | 0.6% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.7M | $-24.8M | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $28.8M | — | ||
| Q4 24 | $49.1M | — | ||
| Q3 24 | $27.6M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $17.5M | — |
| Q4 25 | $49.9M | $-34.8M | ||
| Q3 25 | $28.8M | — | ||
| Q2 25 | $35.5M | — | ||
| Q1 25 | $28.1M | — | ||
| Q4 24 | $48.5M | — | ||
| Q3 24 | $26.7M | — | ||
| Q2 24 | $16.0M | — | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 34.3% | -33.5% | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | 27.9% | — | ||
| Q1 25 | 23.0% | — | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 15.5% | — | ||
| Q1 24 | 16.6% | — |
| Q4 25 | 0.6% | 9.6% | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.8% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FROG
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
